<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-174-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOVEN 1% VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Emulsion for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        As provided in the Drug Summary Bulletin
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        102.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FRESENIUS KABI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Fresenius Kabi Deutschland GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AX10 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Propoven 1% MCT/LCT belongs to a group of medicines called &lsquo;general anaesthetics&rsquo;. General anaesthetics are used to cause unconsciousness (sleep) so that surgical operations or other procedures can be performed. They can also be used to sedate you (so that you are sleepy but not completely asleep).</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify"><strong>Propoven 1% MCT/LCT 10 mg/ml emulsion for injection or infusion is used to:</strong></p><p style="margin-left:39.6pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->induce and maintain general anaesthesia in adults, adolescents and children older than 1 month.</p><p style="margin-left:39.6pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sedate patients older than 16 years of age receiving artificial respiration in intensive care.</p><p style="margin-left:39.6pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sedate adults, adolescents and children older than 1 month during diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:3.6pt; margin-right:0cm"><strong>Do not use Propoven 1% MCT/LCT</strong></p><p style="margin-left:3.6pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Propofol, soya, peanut</p><p style="margin-left:21.6pt; margin-right:0cm">or any of the other ingredients of this</p><p style="margin-left:21.6pt">medicine (listed in section 6).</p><p style="margin-left:3.6pt">- in patients of 16 years of age or younger for</p><p style="margin-left:21.6pt">sedation in intensive care.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p style="text-align:justify">Talk to your doctor, pharmacist or nurse before you are given Propoven 1% MCT/LCT and if any of the subsequent mentioned applies to you or applied to you in the past.</p><p style="text-align:justify">You should not receive Propoven 1% MCT/LCT, or only under extreme caution and intensive monitoring, if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have advanced heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have any other serious disease of the heart</p><p>- are receiving electroconvulsive therapy (ECT,</p><p style="margin-left:18.0pt">a treatment for psychiatric problems)</p><p style="text-align:justify">In general, Propoven 1% MCT/LCT should be given with caution to elderly or weak patients.</p><p style="text-align:justify">Before receiving Propoven 1% MCT/LCT, tell your anaesthetist or intensive care doctor if you have:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disease</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (epilepsy)</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt">- a raised pressure inside the skull (raised intracranial pressure). In combination with low blood pressure the amount of blood reaching the brain may be decreased.</p><p style="margin-left:18.0pt; margin-right:0cm; text-align:justify; text-indent:-18.0pt">- altered levels of fat in the blood. If you are receiving total parenteral nutrition (feeding through a vein), the levels of fat in your blood must be monitored.</p><p style="margin-left:18.0pt; margin-right:0cm; text-align:justify; text-indent:-18.0pt">- if your body has lost lots of water (you are hypovolaemic).</p><p style="text-align:justify">If you have any of the following conditions, they must be treated before you receive Propoven 1% MCT/LCT:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure</p><p>- when there is insufficient blood reaching the</p><p style="margin-left:18.0pt">tissues (circulatory failure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe breathing problems (respiratory failure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration (hypovolaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (epilepsy)</p><p>Propoven 1% MCT/LCT may increase the risk of</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epileptic seizures</p><p>- a nervous reflex that slows the heart rate</p><p style="margin-left:18.0pt">(vagotonia, bradycardia)</p><p style="margin-left:18.0pt; margin-right:0cm; text-align:justify; text-indent:-18.0pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the blood flow to the organs of the body (haemodynamic effects on the cardiovascular system) if you are overweight and receive high doses of Propoven 1% MCT/LCT.</p><p style="text-align:justify">Involuntary movements can occur during sedation with Propoven 1% MCT/LCT. The doctors will take into account how this might affect surgical procedures being performed under sedation and will take the necessary precautions.</p><p style="text-align:justify">Very occasionally, after anaesthesia, there may be a period of unconsciousness associated with stiffness of the muscles. This requires observation by the medical staff but no other treatment. It will resolve spontaneously.</p><p style="text-align:justify">The injection of Propoven 1% MCT/LCT can be painful. A local anaesthetic can be used to reduce this pain but can have its own side effects.</p><p style="text-align:justify">You will not be allowed to leave the hospital until you are fully awake.</p><p style="text-align:justify">If you are able to go home shortly after receiving Propofol you should not go home unaccompanied.</p><p style="text-align:justify"><strong>Children and adolescents</strong></p><p style="text-align:justify">The use of Propoven 1% MCT/LCT 10 mg/ml emulsion for injection or infusion is not recommended for use in new-born infants or children younger than 1 month.</p><p style="text-align:justify">Due to the limited data available, the use of target controlled infusion (TCI) in the paediatric population below 2 years of age cannot be recommended.</p><p style="text-align:justify">Propoven 1% MCT/LCT 10 mg/ml must not be given to children and adolescents younger than 16 years of age for sedation in the intensive care unit, since its safety has not been demonstrated in this patient group for this indication.</p><p style="margin-left:0cm; margin-right:10.8pt"><strong>Other medicines and Propoven 1% MCT/LCT </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor, anaesthetist or nurse if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (for tuberculosis &ndash; TB).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Midazolam (used to induce sedation (a very relaxed state of calm, drowsiness or sleep) and relieves anxiety and muscle tension).</p><p>&nbsp;</p><p>You must take special care if you are also taking/receiving any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premedications (your anaesthetist will know which medicines can be influenced by Propoven 1% MCT/LCT)</p><p><span style="text-align:justify; text-indent:-18pt">- Other anaesthetics, including general, regional, local and inhalational anaesthetics (Lower doses of Propoven 1% MCT/LCT may be required. Your anaesthetist will know this.)</span></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painkillers (analgesics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strong painkillers (fentanyl or opioids)</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt">- Parasympatholytic agents (medicines used to treat e.g. painful cramps of organs, asthma or Parkinson&#39;s disease)</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt">- Benzodiazepines (medicines used to treat anxiety)</p><p style="margin-left:3.6pt">-&nbsp;&nbsp;&nbsp;&nbsp; Suxamethonium (muscle relaxant)</p><p style="margin-left:3.6pt">- Drugs that affect many of the internal body</p><p style="margin-left:14.4pt; margin-right:0cm">functions such as the heart rate, e.g. atropine</p><p style="margin-left:3.6pt">-&nbsp;&nbsp;&nbsp;&nbsp; Alcohol containing medicines or beverages</p><p style="margin-left:3.6pt; margin-right:0cm">- Neostigmine (medicine used to treat a disease</p><p style="margin-left:14.4pt">called myasthenia gravis)</p><p style="margin-left:3.6pt">- Cyclosporine (medicine used to prevent</p><p style="margin-left:14.4pt">transplant rejections)</p><p style="margin-left:3.6pt; margin-right:0cm">- Valproate (medicine used to treat epilepsy or</p><p style="margin-left:14.4pt">mental disorders)</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify"><strong>Propoven 1% MCT/LCT with food, drink and alcohol</strong></p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">After you have been given Propoven 1% MCT/LCT, you should not eat, drink or consume alcohol until fully recovered.</p><p style="margin-left:3.6pt; margin-right:0cm; text-align:justify"><strong>Pregnancy and breastfeeding</strong></p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Propoven 1% MCT/LCT should not be given to pregnant women unless clearly necessary.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">You should stop breast-feeding and discard any breast milk for 24 hours after receiving Propoven 1% MCT/LCT.</p><p style="margin-left:3.6pt; margin-right:0cm"><strong>Driving and using machines</strong></p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">After having Propofol you may still feel sleepy for some time.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Do not drive or use any tools or machines until you are sure the effects have worn off.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">If you are able to go home shortly after receiving Propofol, do not drive a car or go home unaccompanied.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Ask your doctor when you can start doing these activities again and when you can go back to work.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify"><strong>Propoven 1% MCT/LCT contains soya-bean oil and sodium</strong></p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Propoven 1% MCT/LCT contains soya-bean oil. If you are allergic to peanut or soya, do not use this medicinal product.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">This medicinal product contains less than 1 mmol (23 mg) sodium per 100 ml, i.e. essentially &acute;sodium-free`.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Propoven 1% MCT/LCT will only be given to you in hospitals or suitable therapy units by or under the direct supervision of your anaesthetist or intensive care doctor.</p><p style="margin-left:3.6pt; margin-right:0cm; text-align:justify"><strong>Dosage</strong></p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">The dose you are given will vary depending on your age, body weight and physical condition. The doctor will give the correct dose to start and to sustain anaesthesia or to achieve the required level of sedation by carefully watching your responses and vital signs (pulse, blood pressure, breathing, etc.).</p><p style="margin-left:0cm; margin-right:3.6pt; text-align:justify">You may need several different medicines to keep you asleep or sleepy, free from pain, breathing in a healthy way and to keep your blood pressure steady. The doctor will decide which medicines you need and when you need them.</p><p style="margin-left:0cm; margin-right:3.6pt; text-align:justify"><strong>Adults</strong></p><p style="margin-right:3.6pt; text-align:justify">Most people need 1.5 - 2.5 mg Propofol per kg body weight to make them go to sleep (induction of anaesthesia), and then 4 to 12 mg Propofol per kg body weight per hour after this to keep them asleep (maintenance of anaesthesia). For sedation, doses of 0.3 to 4.0 mg Propofol per kg body weight per hour are usually sufficient.</p><p style="margin-left:0cm; margin-right:3.6pt; text-align:justify">For sedation during surgical and diagnostic procedures in adults, most patients will require 0.5 - 1 mg Propofol per kg body weight over 1 to 5 minutes for onset of sedation. Maintenance of sedation may be accomplished by titrating Propoven 1% MCT/LCT infusion to the desired level of sedation. Most patients will require 1.5 - 4.5 mg Propofol per kg body weight per hour. The infusion may be supplemented by bolus administration of 10 - 20 mg Propofol (1 - 2 ml Propoven 1% MCT/LCT 10 mg/ml emulsion for injection or infusion) if a rapid increase of the depth of sedation is required.</p><p style="margin-left:0cm; margin-right:3.6pt; text-align:justify">To provide sedation for ventilated patients older than 16 years of age under intensive care conditions the dose will be adjusted according to the depth of sedation required. Usually satisfactory sedation is achieved by continuous infusion with administration rates in the range of 0.3 to 4.0 mg Propofol per kg body weight per hour. Rates of infusion greater than 4.0 mg Propofol per kg bodyweight per hour are not recommended.</p><p style="margin-left:0cm; margin-right:3.6pt"><strong>Elderly and weak patients</strong></p><p style="margin-right:3.6pt">Elderly and weak patients may require lower doses.</p><p style="margin-left:0cm; margin-right:3.6pt; text-align:justify"><strong>Use in children and adolescents over one month of age</strong></p><p style="margin-right:3.6pt; text-align:justify">The use of Propoven 1% MCT/LCT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is not<br />recommended in children younger than 1 month. Special care should also be observed when administering Propoven 1% MCT/LCT 10 mg/ml emulsion for injection or infusion to children less than 3 years of age. However, evidence now available does not suggest that this is any less safe than in children older than 3 years.</p><p style="margin-right:3.6pt; text-align:justify">The dose should be adjusted according to age and/or body weight. Most patients over 8 years of age require approximately 2.5 mg/kg bodyweight Propoven 1% MCT/LCT to make them go to sleep (induction of anaesthesia). In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher (2.5 - 4 mg/kg bodyweight).</p><p>&nbsp;</p><p style="text-align:justify">Rates in the region of 9 - 15 mg/kg/h usually achieve satisfactory anaesthesia to keep them asleep (maintenance of anaesthesia). In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher.</p><p style="text-align:justify">For sedation during surgical and diagnostic procedures in children over 1 month of age with Propoven 1% MCT/LCT 10 mg/ml emulsion for injection or infusion most paediatric patients require 1 - 2 mg/kg bodyweight Propofol for onset of sedation. Maintenance of sedation may be accomplished by titrating Propoven 1% MCT/LCT infusion to the desired level of sedation. Most patients require 1.5 - 9 mg/kg/h Propofol. The infusion may be supplemented by bolus administration of up to 1 mg/kg bodyweight if a rapid increase of depth of sedation is required.</p><p style="text-align:justify">Propoven 1% MCT/LCT 10 mg/ml emulsion for injection or infusion must not be given to children and adolescents younger than 16 years of age for sedation in the intensive care unit, since its safety has not been demonstrated in this patient group for this indication.</p><p style="text-align:justify"><strong>Method of administration</strong></p><p style="text-align:justify">Propoven 1% MCT/LCT is for intravenous use, usually administered on the back of your hand or in the forearm. Your anaesthetist may use a needle or cannula (a fine plastic tube). Propoven 1% MCT/LCT will be injected into a vein either manually or by electric pumps.</p><p style="text-align:justify">Propoven 1% MCT/LCT is for single use only. Any unused emulsion must be discarded. Containers should be shaken before use If two layers can be seen after shaking the emulsion should not be used. Use only homogeneous preparations and undamaged containers.</p><p style="text-align:justify">Prior to use, the rubber membrane should be cleaned using an alcohol spray or a swab dipped in alcohol.</p><p><strong>Duration of treatment</strong></p><p>When used for sedation, Propoven 1% MCT/LCT</p><p>must not be administered for more than 7 days.</p><p style="margin-left:0cm; margin-right:14.4pt; text-align:justify"><strong>If you received more Propofol than you should </strong>Your doctor will ensure that you receive the right amount of Propofol for you and for the procedure you are undergoing.</p><p style="text-align:justify">However, different people need different doses and if you do receive too much for you, your anaesthetist may need to take measures to make sure your heart and breathing are adequately supported. This is why anaesthetic drugs are only administered by doctors trained in anaesthesia or in the care of patients in intensive care.</p><p style="margin-left:7.2pt; margin-right:3.6pt; text-align:justify">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:7.2pt; margin-right:3.6pt; text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="margin-left:7.2pt; margin-right:3.6pt; text-align:justify"><strong>Side effects that can happen during anaesthesia </strong>The following side effects can happen during anaesthesia (while the injection is being given to you or when you are sleepy or asleep). Your doctor will be looking out for these. If they happen, your doctor will give you appropriate treatment.</p><p style="margin-left:7.2pt; margin-right:3.6pt; text-align:justify"><strong><em>Very common (may affect more than 1 in 10 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A feeling of pain at the site of the injection (while the injection is being given, before you fall asleep).</p><p style="margin-left:7.2pt; margin-right:0cm"><strong><em>Common (may affect up to 1 in 10 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Slow or fast heartbeat</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Low blood pressure</p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Changes in your breathing pattern (low respiratory rate, breathing arrest)</p><p style="margin-left:25.2pt; margin-right:0cm; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hiccups</p><p style="margin-left:25.2pt; margin-right:0cm; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Cough (may also happen when you wake up)</p><p style="margin-left:7.2pt; margin-right:0cm"><strong><em>Uncommon (may affect up to 1 in 100 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Swelling and redness or blood clots at the vein along the injection site.</p><p style="margin-left:7.2pt; margin-right:0cm"><strong><em>Rare (may affect up to 1 in 1,000 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Twitching and shaking of your body, or fits (may also happen when you wake up).</p><p style="margin-left:7.2pt; margin-right:0cm"><strong><em>Very rare (may affect up to 1 in 10, 000 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Serious allergic reaction which causes difficulty in breathing, swollen and reddened skin, hot flushes</p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Build up of fluid in the lungs which can make you very breathless (may also happen when you wake up)</p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Unusual colour of urine (may also happen when you wake up).</p><p style="margin-left:7.2pt; margin-right:3.6pt; text-align:justify"><strong><em>Not known (frequency cannot be estimated from the available data)</em></strong></p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Involuntary movements</p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Severe skin and tissue reaction following accidental application beside the vein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged, often painful erection (priapism).</p><p><strong>&nbsp;</strong></p><p style="margin-left:7.2pt; margin-right:14.4pt"><strong>Side effects that can happen after anaesthesia </strong>The following side effects can happen after anaesthesia (when you are waking up or after you have woken up).</p><p style="margin-left:7.2pt; margin-right:0cm"><strong><em>Common (may affect up to 1 in 10 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Feeling sick (nausea), being sick (vomiting).</p><p style="margin-left:25.2pt; margin-right:0cm; text-align:justify; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Cough.</p><p style="margin-left:3.6pt; margin-right:0cm"><strong><em>Rare (may affect up to 1 in 1,000 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Dizziness, chills and sensations of cold</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Excitations</p><p style="margin-left:3.6pt; margin-right:0cm"><strong><em>Very rare (may affect up to 1 in 10,000 people)</em></strong></p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Being unconscious after the operation (when this has happened, the patients have recovered without problems)</p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Inflamed pancreas (pancreatitis) which causes severe stomach pain (a causal relationship could not be shown)</p><p style="margin-left:25.2pt; margin-right:0cm; text-align:justify; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fever following surgery</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify"><strong><em>Not known (frequency cannot be estimated from the available data)</em></strong></p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Feeling euphoric</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Feeling sexually aroused</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Irregular heart beat</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Changes in ECG (Brugada type ECG)</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Increase in liver size</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Kidney failure</p><p style="margin-left:25.2pt; margin-right:3.6pt; text-align:justify; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breakdown of muscle cells (rhabdomyolysis), increase in acidity of your blood, high potassium and fat levels in your blood, heart failure</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Drug abuse, mostly by healthcare professionals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged, often painful erection (priapism).</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">When Propoven 1% MCT/LCT is administered in combination with lidocaine (a local anaesthetic used to reduce the pain at the site of injection), certain side effects may occur rarely:</p><p style="margin-left:3.6pt; margin-right:0cm">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness<br />&minus; vomiting</p><p style="margin-left:3.6pt; margin-right:0cm">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p style="margin-left:3.6pt">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits</p><p style="margin-left:3.6pt">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a slowing of the heart rate (bradycardia)</p><p style="margin-left:3.6pt; margin-right:32.4pt; text-align:justify">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat (cardiac arrhythmias) &minus; shock</p><p style="margin-left:3.6pt; margin-right:0cm; text-align:justify"><strong>Reporting of side effects</strong></p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed below.</p><p style="margin-left:3.6pt; margin-right:21.6pt"><!--[if gte vml 1]><v:line id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;z-index:251657216;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 from="312.95pt,641.05pt" to="529.7pt,641.05pt" strokeweight=".7pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]-->The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-14.4pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-14.4pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-14.4pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Toll free phone: 19999</p><p style="margin-left:25.2pt; text-indent:-14.4pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa<u> </u></p><p style="margin-left:25.2pt; margin-right:0cm; text-indent:-14.4pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Keep this medicine out of the sight and reach of children.</p><p style="margin-left:3.6pt; margin-right:3.6pt; text-align:justify">Do not use this medicine after the expiry date which is stated on the ampoule/vial and the outer packaging after EXP. The expiry date refers to the last day of that month.</p><p style="margin-left:3.6pt; margin-right:0cm">Do not store above 25 &deg;C.<br />Do not freeze.</p><p style="margin-left:3.6pt; margin-right:18.0pt; text-align:justify">After first opening the medicinal product must be used immediately.</p><p style="margin-left:3.6pt; margin-right:18.0pt; text-align:justify">Administration systems with undiluted Propoven 1% MCT/LCT should be replaced 12 hours after opening of the ampoule or vial. Dilutions with glucose 50 mg/ml (5 %) solution for injection or sodium chloride 9 mg/ml (0.9 %) solution for injection or an admixture with preservative-free lidocaine 10 mg/ml (1 %) solution for injection (at least 2 mg Propofol per ml) should be prepared aseptically (controlled</p><p style="margin-left:3.6pt; margin-right:18.0pt; text-align:justify">and validated conditions preserved) immediately before administration and has to be administered within 6 hours after preparation.</p><p style="margin-left:3.6pt; margin-right:18.0pt; text-align:justify">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:3.6pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is Propofol.</p><p style="margin-left:3.6pt; margin-right:21.6pt">Each ml emulsion contains 10 mg Propofol. Each 20-ml ampoule contains 200 mg Propofol. Each 20-ml vial contains 200 mg Propofol. Each 50-ml vial contains 500 mg Propofol. Each 100-ml vial contains 1000 mg Propofol.</p><p>The other ingredients are soya-bean oil, refined, medium-chain triglycerides, purified egg phosphatides, glycerol, oleic acid, sodium hydroxide, water for injections .</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Propoven 1% MCT/LCT is a white oil-in-water emulsion for injection or infusion.
Propoven 1% MCT/LCT is available in colourless glass ampoules or glass vials. The glass vials are sealed with rubber stoppers.
Pack sizes: 
Packs containing 5 glass ampoules with 20 ml emulsion Packs containing 10 glass ampoules with 20 ml emulsion Packs containing 1 glass vial with 20, 50 or 100 ml emulsion Packs containing 5 glass vials with 20 ml emulsion Packs containing 10 glass vials with 20, 50 or 100 ml emulsion
Packs containing 15 glass vials with 50 or 100 ml emulsion
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fresenius Kabi Deutschland GmbH<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aug 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي ينتمي إلى مجموعة من الأدوية يُطلق عليها الأدوية المخدرة العامة. تستخدم الأدوية المخدرة العامة لإفقاد المريض الوعي (جعله ينام) حتى يمكن القيام بالعمليات الجراحية أو الاجراءات الأخرى. يمكن استخدامها أيضاً لجعلك في حالة من الخدر (حتى تشعر بالنوم، ولكن ليس نائماً تماماً).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>يستخدم بروبوفن 1% إم سي تي / إل سي تي 10 ملغم/مل مستحلب للحقن أو التسريب في:</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->استحثاث التخدير العام والحفاظ عليه لدي البالغين والمراهقين والأطفال الذين تزيد أعمارهم عن شهر واحد.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تهدئة المرضي الذين تزيد أعمارهم عن 16 عاما ويتلقون التنفس الاصطناعي في الرعاية المركزة.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تهدئة الكبار والأطفال الذين تزيد أعمارهم عن شهر واحد أثناء الاجراءات التشخيصية والجراحية سواءً بمفرده أو بالاشتراك مع الأدوية المخدرة الموضعية والعامة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right"><strong>لا تستخدم بروبوفن 1% إم سي تي / إل سي تي&nbsp; </strong></p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:14.2pt; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك تحسس من البروبوفول، فول الصويا، الفول السوداني أو اي من المكونات الأخرى لهذا الدواء (المدرجة في المادة 6).</p><p dir="RTL" style="margin-left:14.2pt; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المرضى البالغين من العمر 16 سنة أو أقل الذين يحتاجون للتهدئة في وحدة العناية المركزة.</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; text-align:right"><strong>المحاذير والاحتياطات </strong></p><p dir="RTL">- يُرجى استشارة الطبيب أو الصيدلي أو المُمرضة قبل استخدام دواء &quot;بروبوفن 1% أم سي تي/إل سي تي&quot;، وفي حالة إن كان ينطبق عليك حالياً أو فيما مضى أي مما هو مذكور لاحقاً في هذه النشرة.</p><p dir="RTL">- وفي هذا الصدد، ينبغي عدم تعاطي دواء &quot;بروبوفن 1% أم سي تي/إل سي تي&quot;، أو تعاطيه فقط بشرط الحذر الشديد والرقابة الوثيقة، مع أي من الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل القلب المتقدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أحد أمراض القلب الخطيرة الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بالصدمات الكهربائية &quot;ECT&quot; (وهو أحد علاجات المشكلات النفسية).</p><p dir="RTL" style="text-align:right">بشكل عام، ينبغي ان يعطي بروبوفن 1% إم سي تي / إل سي تي بحذر للمسنين أو المرضي الضعفاء.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قبل تلقي بروبوفن 1% إم سي تي / إل سي تي، أخبر طبيب التخدير أو العناية المركزة إذا كان لديك:</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->امراض القلب</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->امراض الرئة</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->امراض الكلي</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->امراض الكبد</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تشنجات (الصرع)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ارتفاع الضغط داخل الجمجمة (ضغط المخ الداخلي المرفوع). الاقتران مع انخفاض ضغط الدم، قد ينخفض مقدار الدم الذي يصل إلى المخ.</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تغيير مستويات الدهون في الدم. إذا كنت تتلقي التغذية الوريدية الكاملة (التغذية من خلال الوريد)، فيجب رصد مستويات الدهون في دمك.</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان جسمك قد فقد الكثير من الماء (كنت تعاني من انخفاض حجم الدم).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">إذا كان لديك اي من الحالات التالية، يجب معالجتها قبل تلقي بروبوفن 1% إم سي تي / إل سي تي:</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فشل القلب</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عندما يكون هناك نقص في وصول الدم إلى الأنسجة (فشل في الدورة الدموية)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مشاكل التنفس الحادة (فشل الجهاز التنفسي)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجفاف (انخفاض حجم الدم)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التشنجات (الصرع)</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي قد يزيد من خطر</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نوبات الصرع</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->رد فعل في الجهاز العصبي يبطئ معدل ضربات القلب (غَلَبَةُ المُبْهَم، بطء القلب)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التغيرات في تدفق الدم إلى أجهزه الجسم (التأثيرات الديناميكية الدموية على الجهاز الدوري) إذا كنت تعاني من زيادة الوزن وتتلقي جرعات عالية من بروبوفن 1% إم سي تي / إل سي تي.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">يمكن ان تحدث حركات لا إرادية اثناء التخدير مع بروبوفن 1% إم سي تي / إل سي تي. سيأخذ الأطباء في الاعتبار كيف يمكن ان يؤثر ذلك على الإجراءات الجراحية التي تجري تحت التخدير وسيقومون باتخاذ الاحتياطات اللازمة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">في بعض الأحيان، وبعد التخدير، قد تكون هناك فتره من عدم الوعي متزامنة مع تصلب العضلات. وهذا يتطلب المراقبة من جانب الممارسين الصحيين ولكن دون علاج آخر. وسوف تنتهي تلقائيا.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حقن بروبوفن 1% إم سي تي / إل سي تي يمكن ان تكون مؤلمه. ويمكن استخدام التخدير الموضعي للحد من هذا الم ولكن يمكن ان يكون له اثاره الجانبية الخاصة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لن يسمح لك بمغادره المستشفى حتى تستيقظ تماما</p><p dir="RTL" style="text-align:right">إذا كنت قادرا على العودة إلى منزلك بعد فتره وجيزة من تلقي بروبوفول يجب ان لا تذهب إلى المنزل دون مرافق.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">الأطفال والمراهقون</p><p dir="RTL" style="text-align:right">لا ينصح باستخدام بروبوفن 1% إم سي تي / إل سي تي 10 ملغم/مل مستحلب للحقن أو التسريب للرضع المولودين حديثا أو الأطفال الذين تقل أعمارهم عن شهر واحد.</p><p dir="RTL" style="margin-left:0cm; text-align:right">نظرا لمحدودية المعلومات المتاحة، لا يمكن التوصية باستخدام التسريب المراقب المستهدف (تي سي أي) في الأطفال الذين تقل أعمارهم عن سنتين.</p><p dir="RTL" style="text-align:right">يجب الا يعطي بروبوفن 1% إم سي تي / إل سي تي 10 ملغ/مل للأطفال والمراهقين الذين تقل أعمارهم عن 16 سنه لتخديرهم في وحده العناية المركزة، لان هذا الاستخدام لم تثبت سلامته في هذه المجموعة من المرضى.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL"><strong>استخدام دواء &quot;بروبوفن 1% أم سي تي/إل سي تي&quot; مع الأدوية الأخرى</strong></p><p dir="RTL">&times; لابد من استشارة الطبيب أو الصيدلي، إذا كنت تأخذ حالياً أو قد أخذت مؤخرًا أو سوف تأخذ قريباً أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times;وبشكل خاص، فلابد من استشارة الطبيب المعالج أو طبيب التخدير أو الممرضة، في حالة تعاطي المريض لأي من الأدوية الآتية:</p><p dir="RTL">- دواء &quot;ريفامبيسين&quot; (المُستخدم في علاج مرض السل).</p><p dir="RTL">- دواء &quot;ميدازولام&quot; (المُستخدم في حث حالة التهدئة (وهي حالة استرخاء شديدة من الهدوء أو النعاس أو النوم)؛ كما يُستخدم أيضاً في التخفيف من حِدة القلق والتوتر العضلي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; ولابد من توخي العناية الخاصة في حالة إن كنت تتلقى/تتعاطى أي من الأدوية الآتية:</p><p dir="RTL">- أدوية تمهيد التخدير (فلابد أن يكون طبيب التخدير على دراية كاملة بالأدوية التي يمكن تأثر مفعولها باستخدام دواء &quot;بروبوفن 1% أم سي تي/إل سي تي&quot;).</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدوية التخدير الأخرى، بما في ذلك التخدير العام والجزئي والموضعي والمستنشقات (ربما يلزم اعطاء جرعات أقل من بروبوفن 1% إم سي تي / إل سي تي. سوف يوضح لك ذلك طبيب التخدير الخاص بك)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المسكنات (مسكنات الألم)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المسكنات القوية (الفنتانيل أو شبائه الأفيون)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مثبطات الجهاز العصبي الباراسيمبتاوي (الأدوية المستخدمة لعلاج التشنجات مؤلمه للأعضاء، أو الربو أو مرض باركنسون)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البنزوديازيبينات (الأدوية المستخدمة لعلاج القلق)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سوكساميثنيوم (مرخي للعضلات)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المخدرات التي تؤثر على العديد من وظائف الجسم الداخلي مثل معدل ضربات القلب، مثل الأتروبين</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية أو المشروبات التي تحتوي على الكحول</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->النيوستيجمين (دواء يستخدم لعلاج مرض يسمي الوهَنٌ العَضَلِيٌّ الوَبيل)</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->السيكلوسببورينات (الأدوية المستخدمة لمنع الرفض في زراعة الأعضاء والأنسجة)&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فالبيوريت (الدواء المستخدم لعلاج الصرع أو الاضطرابات العقلية).</p><p dir="RTL" style="margin-left:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي مع الطعام والشراب والكحول</p><p dir="RTL" style="margin-left:0cm; text-align:right">بعد ان تعطى بروبوفن 1% إم سي تي / إل سي تي، يجب ان لا تأكل أو تشرب أو تتناول الكحول حتى تتعافي تماما.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL" style="margin-left:0cm; text-align:right">إذا كنت حاملا أو مرضعة، تعتقدين بأنك قد تكوني حاملا أو تخططين للحمل، اطلبي من طبيبك تقديم المشورة قبل إعطاءك الدواء.</p><p dir="RTL" style="margin-left:0cm; text-align:right">بروبوفن 1% إم سي تي / إل سي تي لا ينبغي ان يعطي للنساء الحوامل ما لم يكن ذلك ضروريا بشكل واضح.</p><p dir="RTL" style="margin-left:0cm; text-align:right">يجب وقف الرضاعة الطبيعية والتخلص من اي لبن من الثدي لمده 24 ساعة بعد تلقي بروبوفن 1% إم سي تي / إل سي تي.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL" style="margin-left:0cm; text-align:right">بعد بروبوفول قد لا تزال تشعر بالنعاس لبعض الوقت.</p><p dir="RTL" style="margin-left:0cm; text-align:right">&nbsp;لا تقود أو تستخدم اي أدوات أو آلات حتى تكون على يقين من ان تلك الآثار قد انتهت.</p><p dir="RTL" style="margin-left:0cm; text-align:right">إذا كنت قادرا على العودة إلى المنزل بعد فتره وجيزة من تلقي بروبوفول، لا تقود السيارة أو تذهب إلى المنزل دون مرافق.</p><p dir="RTL" style="margin-left:0cm; text-align:right">أسال طبيبك عن متى يمكنك البدء في القيام بهذه الأنشطة مره أخرى وعن متى يمكنك العودة إلى العمل.</p><p dir="RTL" style="margin-left:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0cm; text-align:right"><strong>يحتوي بروبوفن 1% إم سي تي / إل سي تي علي زيت فول الصويا والصوديوم</strong></p><p dir="RTL" style="text-align:right">يحتوي بروبوفن 1% إم سي تي / إل سي تي&nbsp;&nbsp; على زيت فول الصويا. إذا كانت لديك حساسية من الفول السوداني أو فول الصويا، لا تستخدم هذا المنتج الطبي.</p><p dir="RTL" style="margin-left:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; text-align:right">يحتوي هذا المنتج الطبي علي اقل من 1 ملمول (23 ملغ) صوديوم لكل 100 مل، اي &quot;خال جوهريا من الصوديوم&quot;.</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">لن تعطي بروبوفن 1% إم سي تي / إل سي تي الا في المستشفيات أو وحدات العلاج المناسبة من قبل أو تحت اشراف مباشر من طبيب التخدير الخاص أو العناية المركزة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>الجرعة</strong></p><p dir="RTL" style="text-align:right">سوف تعطي جرعة تختلف حسب عمرك، ووزن الجسم والحالة البدنية. وسوف يعطي الطبيب الجرعة الصحيحة للبدء والحفاظ على التخدير أو لتحقيق المستوي المطلوب من التخدير عن طريق مراقبه ردودك وعلاماتك الحيوية بعناية (النبض، وضغط الدم، والتنفس، الخ).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قد تحتاج العديد من الأدوية المختلفة لإبقائك نائما أو نعسانا، غير شاعر بالألم، متنفسا بطريقه صحية وتعمل على الحفاظ على ضغط الدم الثابت. سيقرر الطبيب الأدوية التي تحتاج اليها وعندما تحتاج اليها.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الكبار</strong></p><p dir="RTL" style="text-align:right">معظم الناس في حاجه 1.5-2.5 ملغ البروبوفول للكيلوغرام من وزن الجسم لجعلها تذهب إلى النوم (استحثاث التخدير)، ومن ثم 4 حتى 12 ملغ من البروبوفول لكل كيلوغرام من وزن الجسم في الساعة بعد ذلك لإبقائهم نائمين (الحفاظ على التخدير). للتهدئة، فان جرعات 0.3 إلى 4.0 مغ بروبوفول لكل كيلوغرام من وزن الجسم في الساعة تكفي عاده.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; text-align:right">للتهدئة خلال الإجراءات الجراحية والتشخيصية في البالغين ومعظم المرضي سوف تتطلب 0.5-1 ملغ من البروبوفول للكيلوغرام من وزن الجسم لنحو 1 إلى 5 دقائق لبدء التهدئة. ويمكن الحفاظ على التهدئة من خلال معايرة ضخ بروبوفن 1% إم سي تي / إل سي تي إلى المستوي المطلوب من التهدئة. سيتطلب معظم المرضي 1.5-4.5 ملغ بروبوفول لكل كيلوغرام من وزن الجسم في الساعة. ويمكن استكمال التسريب بإعطاء جرعة واحدة 10-20 ملغ بروبوفول (1-2 مل بروبوفن 1% إم سي تي / إل سي تي 10 ملغم/مل مستحلب للحقن أو التسريب) إذا كانت هناك حاجه إلى زيادة سريعة في عمق التخدير.</p><p dir="RTL" style="margin-left:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لتوفير التهدئة للمرضي الذين تزيد أعمارهم عن 16 عاما في ظروف الرعاية المركزة، سيتم تعديل الجرعة وفقا للعمق المطلوب للتهدئة. وعاده ما يتحقق التهدئة المرضية عن طريق الضخ المستمر مع معدلات إعطاء في نطاق 0.3 إلى 4.0 ملغ لكل كيلوغرام من وزن الجسم في الساعة. لا ينصح بمعدلات ضخ أكبر من 4.0 ملغ بروبوفول للكيلو وزن الجسم للساعة الواحدة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>المسنون والمرضي الضعفاء</strong></p><p dir="RTL" style="text-align:right">قد يحتاج المسنون والمرضي الضعفاء إلى جرعات اقل.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ال</strong><strong>استخدام في الأطفال والمراهقين الذين تتجاوز أعمارهم شهرا واحدا</strong></p><p dir="RTL" style="text-align:right">لا ينصح باستخدام بروبوفن 1% إم سي تي / إل سي تي في الأطفال الذين تقل أعمارهم عن شهر واحد.</p><p dir="RTL" style="text-align:right">وينبغي أيضا الرعاية الخاصة عند إعطاء بروبوفن 1% إم سي تي / إل سي تي 10 ملغم/مل مستحلب للحقن أو التسريب للأطفال الذين تقل أعمارهم عن 3 سنوات. غير ان المعلومات المتاحة الآن لا توحي بان هذا السن اقل أمانا منه في الأطفال الذين تزيد أعمارهم عن 3 سنوات.</p><p dir="RTL" style="text-align:right">ينبغي تعديل الجرعة وفقا للسن و/أو وزن الجسم. معظم المرضي الذين تزيد أعمارهم على 8 سنوات يحتاجون إلى حوالي 2.5 ملغ/كلغ وزن الجسم بروبوفن 1% إم سي تي / إل سي تي لجعلهم يذهبون إلى النوم (استحثاث التخدير). وفي الأطفال الأصغر سنا، ولا سيما الذين تتراوح أعمارهم بين شهر واحد وثلاث سنوات، قد تكون متطلبات الجرعات أعلي (2.5-4 ملغ/كغ وزن الجسم).</p><p dir="RTL" style="text-align:right">المعدلات في حدود من 9-15 ملغم/كغ/ساعة عاده ما تحقق التخدير المرضي لإبقائهم نائمين (الحفاظ على التخدير). وفي الأطفال الأصغر سنا، ولا سيما الذين تتراوح أعمارهم بين شهر واحد وثلاث سنوات، قد تكون الاحتياجات من الجرعات اعلي.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">للتهدئة خلال الإجراءات الجراحية والتشخيصية في الأطفال أكثر من 1 شهر من العمر، معظم المرضي الأطفال تتطلب 1-2 ملغ/كغ وزن الجسم من بروبوفن 1% إم سي تي / إل سي تي 10 ملغم/مل مستحلب للحقن أو الضخ لبدء التهدئة. ويمكن الحفاظ على التهدئة من خلال معايرة ضخ بروبوفن 1% إم سي تي / إل سي تي إلى المستوي المطلوب من التهدئة. ويحتاج معظم المرضي إلى بروبوفول 1.5 -9 ملغ/كلغ/ساعة. ويمكن تكميل التسريب بإعطاء جرعة واحدة تصل إلى 1 مغ/كغ من وزن الجسم إذا كانت هناك حاجه إلى زيادة سريعة في عمق التهدئة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">يجب الا يعطي بروبوفن 1% إم سي تي / إل سي تي 10 ملغم/مل مستحلب للحقن أو الضخ للأطفال والمراهقين الذين تقل أعمارهم عن 16 سنه لتهدئتهم في وحده العناية المركزة، لان هذا الاستخدام لم تثبت سلامته في هذه المجموعة من المرضى.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>طريقه الإعطاء</strong></p><p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي هو للاستخدام الوريدي، وعاده ما يعطى لك في ظهر يدك أو في الساعد. يمكن لأخصائي التخدير لديك أ يستخدم ابره أو كانيولا (أنبوب بلاستيكي دقيق). سيتم ضخ بروبوفن 1% إم سي تي / إل سي تي في الوريد اما يدويا أو بواسطة مضخات كهربائية.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي للاستخدام الفردي فقط. يجب تجاهل اي مستحلب غير مستخدم. وينبغي ان ترج العبوة قبل استخدامها إذا كان يمكن رؤية طبقتين بعد رج المستحلب لا ينبغي استخدامه. تستخدم المستحضرات المتجانسة فقط والحاويات غير التالفة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قبل الاستخدام، ينبغي تنظيف الغشاء المطاطي باستخدام رذاذ الكحول أو مسحه من الكحول.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>مده العلاج</strong></p><p dir="RTL" style="text-align:right">عندما يستخدم للتهدئة، لا يجب ان يعطى بروبوفن 1% إم سي تي / إل سي تي لأكثر من 7 أيام</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>إذا تلقيت بروبوفول أكثر مما يجب</strong></p><p dir="RTL" style="text-align:right">طبيبك سيضمن لك ان تتلقي الكمية المناسبة من بروبوفول لك وللإجراءات التي تمر بها.</p><p dir="RTL" style="text-align:right">ومع ذلك، قد يحتاج الناس على اختلافهم جرعات مختلفة، وإذا كنت لا تتلقي الكمية الكافية بالنسبة لك، قد يحتاج طبيب التخدير الخاص بك لاتخاذ تدابير للتأكد من أن القلب والتنفس مدعومان بشكل كاف. وهذا هو السبب في ان العقاقير المخدرة لا تعطى الا بواسطة أطباء مدربين على التخدير أو رعاية المرضي في أقسام العناية المركزة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">إذا كان لديك اي أسئلة أخرى حول استخدام هذا الدواء، أسال طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل كل الأدوية، هذا الدواء يمكن ان يسبب اثار جانبيه، على الرغم من ان الجميع لا يحصل عليها.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL">من الممكن حدوث الآثار الجانبية المذكورة أدناه أثناء التخدير (أي أثناء إعطاء الدواء للمريض عبر الحقن، أو أثناء حالة النوم أو النعاس). ولذلك، يختص الطبيب المعالج بمراقبة إمكانية حدوث هذه الآثار؛ وفي حالة حدوثها، سوف يقوم الطبيب بإعطاء العلاج المناسب للمريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار شائعة جداً</strong> (قد تؤثر على أكثر من 1 في كل 10 أفراد):</p><p dir="RTL">- الشعور بالألم في موضع الحقن (وذلك أثناء إعطاء الدواء عبر الحقن قبل انتقال المريض إلى حالة النوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار شائعة </strong>(قد تؤثر على 1 في كل 10 أفراد):</p><p dir="RTL">- تباطؤ أو تسارع ضربات القلب.</p><p dir="RTL">- انخفاض ضغط الدم.</p><p dir="RTL">- حدوث تغييرات في نمط التنفس لدى المريض (مثل: انخفاض معدل التنفس، أو توقف التنفس).</p><p dir="RTL">- الإصابة بنوبة الفواق.</p><p dir="RTL">- الكحة (والتي قد تحدث عند استيقاظ المريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار غير شائعة </strong>(قد تؤثر على 1 في كل 100 فرد):</p><p dir="RTL">- حدوث تورم واحمرار أو جلطات دموية في الوريد على طول موضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار نادرة </strong>(قد تؤثر على 1 في كل 1000 فرد):</p><p dir="RTL">- حدوث ارتعاش ورجف بجسم المريض أو نوبات مرضية (والتي قد تحدث أيضاً عند استيقاظ المريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار نادرة جداً </strong>(قد تؤثر على 1 في كل 10000 فرد):</p><p dir="RTL">- حدوث رد فعل تحسسي خطير، مما يؤدي إلى صعوبة في التنفس، وتورم واحمرار الجلد، وتوهجات ساخنة.</p><p dir="RTL">- تجمع السوائل في الرئتين، والذي قد يؤدي إلى ضيق حاد في التنفس (وقد يحدث أيضاً عند استيقاظ المريض).</p><p dir="RTL">- ظهور البول بلون غير معتاد (وقد يحدث أيضاً عند استيقاظ المريض).</p><p dir="RTL">&times; <strong>آثار غير معروفة </strong>(حيث لا يمكن تقدير معدل تكرار حدوث هذه الآثار بناء على البيانات المتاحة):</p><p dir="RTL">- حدوث حركات غير إرادية.</p><p dir="RTL">- حدوث رد فعل حاد بالجلد والأنسجة بعد التطبيق غير المقصود لإبرة الحقن بجوار الوريد.</p><p dir="RTL">- حدوث انتصاب مطول، ومؤلم في كثير من الأحيان (القُسَاح).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الآثار الجانبية التي قد تحدث بعد التخدير</strong></p><p dir="RTL">من الممكن حدوث الآثار الجانبية المذكورة أدناه بعد التخدير (أي أثناء استيقاظ المريض، أو بعد استيقاظ المريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار شائعة </strong>(قد تؤثر على 1 في كل 10 أفراد):</p><p dir="RTL">- صُداع الرأس.</p><p dir="RTL">- الشعور بالغثيان (الغثيان)، أو الاِستِفراغ (التقيؤ).</p><p dir="RTL">- الكحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار نادرة </strong>(قد تؤثر على 1 في كل 1000 فرد):</p><p dir="RTL">- الدوخة، والقشعريرة، والإحساس بالبرد.</p><p dir="RTL">- نوبات التهيّج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار نادرة جداً </strong>(قد تؤثر على 1 في كل 10000 فرد):</p><p dir="RTL">- فقدان الوعي بعد إجراء العملية (وحينما حدث ذلك، تعافى المرضى من هذه الحالة دون أي مشكلات).</p><p dir="RTL">- التهاب البنكرياس (داء اِلْتِهابُ البَنْكرِياس)، والذي يؤدي إلى ألم حاد بالمعدة (وقد تعذّر الكشف عن أي علاقة سببية لذلك).</p><p dir="RTL">- الإصابة بالحُمى بعد الجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&times; <strong>آثار غير معروفة </strong>(حيث لا يمكن تقدير معدل تكرار حدوث هذه الآثار بناء على البيانات المتاحة):</p><p dir="RTL">- الشعور بالبهجة.</p><p dir="RTL">- الشعور بالاستثارة الجنسية.</p><p dir="RTL">- اضطراب نبضات القلب.</p><p dir="RTL">- حدوث تغييرات في تخطيط كهربية القلب (تخطيط كهربية القلب من النوع &quot;بروجادا&quot;).</p><p dir="RTL">- زيادة في حجم الكبد.</p><p dir="RTL">- الفشل الكلوي.</p><p dir="RTL">- انهيار خلايا العضلات (انْحِلاَلُ الرُّبَيْدَات)، مما يؤدي إلى زيادة الحموضة في الدم، وارتفاع مستويات البوتاسيوم والدهون في الدم، وفشل القلب.</p><p dir="RTL">- إساءة استخدام الأدوية والعقاقير، والذي غالباً ما يكون من قِبل بعض متخصصي الرعاية الصحية.</p><p dir="RTL">- حدوث انتصاب مطول، ومؤلم في كثير من الأحيان (القُسَاح).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وفي حالة إعطاء دواء &quot;بروبوفن 1% أم سي تي/إل سي تي&quot; بالاشتراك مع دواء &quot;ليدوكائين&quot; (وهو مُخدر موضعي يُستخدم للحد من الألم في موضع الحقن)، قد تظهر الآثار الجانبية التالية بشكل نادر</strong>:</p><p dir="RTL">- الدوخة.</p><p dir="RTL">- التقيؤ.</p><p dir="RTL">- النعاس.</p><p dir="RTL">- نوبات مرضية.</p><p dir="RTL">- تباطؤ معدل ضربات القلب (بطء القلب).</p><p dir="RTL">- اضطراب نبضات القلب (عدم انتظام ضربات القلب).</p><p dir="RTL">- السَّكتة الدِّماغية.</p><p dir="RTL" style="text-align:right"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL" style="text-align:right">إذا كنت تحصل علي أي آثار جانبيه ، تحدث إلى طبيبك ، الصيدلي أو ممرضه. ويشمل ذلك اي أثار جانبية غير مدرجه في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشره عن طريق نظام الإبلاغ الوطني كما هو موضح:</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية</strong>:</p><p dir="RTL"><strong>المركز الوطني لليقظة والسلامة الدوائيَّة </strong><strong>NPC</strong>:</p><p dir="RTL">- مركز اتصالات &quot;الهيئة العامة للغذاء والدواء&quot; بالمملكة العربية السعودية: 19999.</p><p dir="RTL">- البريد الإلكتروني: <u>n</u>pc.drug@sfda.gov.sa</p><p dir="RTL">- الموقع الإلكتروني: <u>https://ade.sfda.gov.sa/</u></p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الإمارات العربية المتحدة</strong>:</p><p dir="RTL"><strong>قسم اليقظة والسلامة الدوائيَّة والأجهزة الطبية</strong>:</p><p dir="RTL">- صندوق بريد رقم: 1853.</p><p dir="RTL">- الهاتف: 80011111.</p><p dir="RTL">- البريد الإلكتروني: <u>pv@mohap.gov.ae</u></p><p>قسم الأدوية والعقاقير-&nbsp; وزارة الصحة ووقاية المجتمع &ndash; دبي &ndash; الإمارات العربية المتحدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول مجلس التعاون الخليجي</strong> <strong>الأخرى</strong>:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُرجى التواصُل مع الجهات المُختصة والمعنية.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أحتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL" style="text-align:right">لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور علي الكرتون والذي يرد على الملصق بعد EXP. ويشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لا تخزن فوق 25 درجه مئوية.</p><p dir="RTL" style="text-align:right">لا تجمد.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">بعد أول فتح لهذا المنتج الطبي يجب ان تستخدم على الفور.</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">ينبغي تغيير أجهزة الإعطاء للبروبوفن 1% إم سي تي / إل سي تي غير المخفف بعد 12 ساعة من افتتاح الأمبوله أو القارورة.</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">التخفيف مع الجلوكوز 50 ملغم/مل (5 ٪) محلول للحقن أو كلوريد الصوديوم 9 ملغ/مل (0.9 ٪) محلول للحقن أو الخلط مع الليدوكين 10 ملغ/مل (1 ٪) الخالي من المواد الحافظة، وينبغي اعداد محلول للحقن (لا يقل عن 2 ملغ من البروبوفول لكل مل) وذلك على الفور قبل الإعطاء ويجب ان يعطى في غضون 6 ساعات بعد الاعداد.</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">لا تتخلص من اي دواء عن طريق المياه العادمة أو النفايات المنزلية. أسال الصيدلي الخاص بك كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL" style="margin-left:14.2pt; margin-right:0cm; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">ما يحتوي عليه بروبوفن 1% إم سي تي / إل سي تي 10 ملغ/مل</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المادة الفعالة هي بروبوفول.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">كل مل مستحلب يحتوي على 10 ملغ بروبوفول.</p><p dir="RTL" style="text-align:right">كل أمبول 20 مل يحتوي على 200 ملغ بروبوفول.</p><p dir="RTL" style="margin-left:0cm; text-align:right">كل قارورة 20 مل تحتوي على 200 ملغ بروبوفول.</p><p dir="RTL" style="text-align:right">تحتوي كل قنينة 50 مل على 500 ملغ من البروبوفول.</p><p dir="RTL" style="text-align:right">تحتوي كل قنينة 100 مل على 1000 ملغ من البروبوفول.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المكونات الأخرى هي زيت فول الصويا المكرر، الدهون الثلاثية ذات سلسله متوسطة، فوسفات البيض المنقي، الجليسيرول، حامض الاولييك، هيدروكسيد الصوديوم، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي هو مستحلب زيت في الماء أبيض للحقن أو التسريب.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">بروبوفن 1% إم سي تي / إل سي تي يتوفر في أمبولات زجاجيه عديمة اللون أو قوارير زجاجيه. والقنينات الزجاجية محكمة الغلق بالمطاط.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><u>حجم العبوة:</u></p><p dir="RTL" style="text-align:right">عبوات تحتوي 5 أمبولات زجاجيه لمستحلب 20 مل</p><p dir="RTL" style="text-align:right">عبوات تحتوي 10 أمبولات زجاجيه لمستحلب 20 مل</p><p dir="RTL" style="text-align:right">عبوات تحتوي قارورة زجاجيه واحده لمستحلب 20 أو 50 أو 100 مل</p><p dir="RTL" style="text-align:right">عبوات تحتوي 5 قوارير زجاجيه لمستحلب 20 مل</p><p dir="RTL" style="text-align:right">عبوات تحتوي 10 قوارير زجاجيه لمستحلب 20 أو 50 أو 100 مل</p><p dir="RTL" style="text-align:right">عبوات تحتوي على 15 قارورة زجاجيه لمستحلب 50 أو 100 مل</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0cm; text-align:right">قد لا يتم تسويق جميع أحجام العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>فريزنيوس كابي دويتشلاند جي إم بي إتش</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أوقست 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml emulsion contains 10 mg propofol.
Each 20 ml ampoule contains 200 mg propofol. 
Each 20 ml vial contains 200 mg propofol. 
Each 50 ml vial contains 500 mg propofol. 
Each 100 ml vial contains 1000 mg propofol.
Excipients with known effect:  
Each ml emulsion contains:
soya-bean oil, refined	50 mg
sodium	max. 0.06 mg
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emulsion for injection or infusion 
White oil-in-water emulsion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion is a short-acting intravenous general anaesthetic for</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; induction and maintenance of general anaesthesia in adults, adolescents and children &gt; 1 month</p><p style="margin-left:28.8pt; text-align:justify; text-indent:-28.8pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults, adolescents and children &gt; 1 month</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sedation of ventilated patients &gt; 16 years of age in the intensive care unit</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Target Controlled Infusion </u></strong><strong><u>&ndash; </u></strong><strong><u>Administration of Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion by pumps (for 20 ml plastic and 50 ml plastic syringe only): </u></strong></p><p style="margin-left:0cm; margin-right:3.6pt">Administration of Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion by a Target Controlled Infusion system is restricted to induction and maintenance of general anaesthesia in adults. It is not recommended for use in ICU sedation or sedation for surgical and diagnostic procedures.</p><p>Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion may be administered by a Target Controlled Infusion system incorporating appropriate Target Controlled Infusion software. Users must be familiar with the infusion pump users&#39; manual, and with the administration of Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion by Target Controlled Infusion.</p><p style="margin-left:0cm; margin-right:14.4pt">The system allows the anaesthetist or intensivist to achieve and control a desired speed of induction and depth of anaesthesia by setting and adjusting target (predicted) plasma and/or effect-side concentrations of propofol.</p><p style="margin-left:0cm; margin-right:14.4pt">Different modalities of the various pump systems should be considered i.e. the Target Controlled Infusion system might assume that the initial blood propofol concentration in the patient is zero. Therefore, in patients who have received prior propofol, there may be a need to select a lower initial target concentration when commencing Target Controlled Infusion. Similarly, the immediate recommencement of Target Controlled Infusion is not recommended if the pump has been switched off.</p><p>Guidance on propofol target concentrations is given below. In view of interpatient variability in propofol pharmacokinetics and pharmacodynamics, in both premedicated and unpremedicated patients the target propofol concentration should be titrated against the response of the patient in order to achieve the depth of anaesthesia required.</p><p><em>Induction and Maintenance of General Anaesthesia during target controlled infusion</em></p><p style="margin-left:0cm; margin-right:18.0pt">In adult patients under 55 years of age anaesthesia can usually be induced with target propofol concentrations in the region of 4 &ndash; 8 microgram/ml. An initial target of 4 microgram/ml is recommended in premedicated patients and in unpremedicated patients an initial target of 6 microgram/ml is advised. Induction time with these targets is generally within the range of 60&ndash;120 seconds. Higher targets will allow more rapid induction of anaesthesia but may be associated with more pronounced haemodynamic and respiratory depression.</p><p style="margin-left:0cm; margin-right:18.0pt; text-align:justify">A lower initial target concentration should be used in patients over the age of about 55 years and in patients of ASA grades 3 and 4. The target concentration can then be increased in steps of 0.5 &ndash; 1.0 microgram/ml at intervals of 1 minute to achieve a gradual induction of anaesthesia.</p><p style="margin-left:0cm; margin-right:3.6pt">Supplementary analgesia will generally be required and the extent to which target concentrations for maintenance of anaesthesia can be reduced will be influenced by the amount of concomitant analgesia</p><p>&nbsp;</p><p style="margin-left:0cm; margin-right:25.2pt">administered. Target propofol concentrations in the region of 3&ndash;6 microgram/ml usually maintain satisfactory anaesthesia.</p><p style="margin-left:0cm; margin-right:10.8pt; text-align:justify">The predicted propofol concentration on waking is generally in the region of 1.0 &ndash; 2.0 microgram/ml and will be influenced by the amount of analgesia given during maintenance.</p><p><em>Sedation during intensive care (target controlled infusion not advised)</em></p><p style="margin-left:0cm; margin-right:7.2pt">Target blood propofol concentration settings in the range of 0.2 &ndash; 2.0 microgram/ml will generally be required. Administration should begin at low target setting which should be titrated against the response of the patient to achieve the depth of sedation desired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol is contraindicated in patients with a known hypersensitivity to propofol or any of the excipients listed in section 6.1.
Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion contains soya oil and should not be used in patients who are hypersensitive to peanut or soya.
Propofol must not be used in patients of 16 years of age or younger for sedation for intensive care (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Propofol should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the care of patients in Intensive Care).</p><p style="text-align:justify">Patients should be constantly monitored and facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and other resuscitative facilities should be readily available at all times. Propofol should not be administered by the person conducting the diagnostic or surgical procedure.</p><p style="text-align:justify">Abuse of and dependence on propofol, predominantly by health care professionals, have been reported. As with other general anaesthetics, the administration of propofol without airway care may result in fatal respiratory complications.</p><p style="text-align:justify">When propofol is administered for conscious sedation, for surgical and diagnostic procedures, patients should be continually monitored for early signs of hypotension, airway obstruction and oxygen desaturation.</p><p style="text-align:justify">As with other sedative agents, when propofol is used for sedation during operative procedures, involuntary patient movements may occur. During procedures requiring immobility these movements may be hazardous to the operative site.</p><p style="text-align:justify">An adequate period is needed prior to discharge of the patient to ensure full recovery after use of propofol. Very rarely the use of propofol may be associated with the development of a period of post&shy;operative unconsciousness, which may be accompanied by an increase in muscle tone. This may or may not be preceded by a period of wakefulness. Although recovery is spontaneous, appropriate care of an unconscious patient should be administered.</p><p>&nbsp;</p><p style="text-align:justify">Propofol induced impairment is not generally detectable beyond 12 hours. The effects of propofol, the procedure, concomitant medications, the age and the condition of the patient should be considered when advising patients on:</p><p style="margin-left:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The advisability of being accompanied on leaving the place of administration</p><p style="margin-left:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The timing of recommencement of skilled or hazardous tasks such as driving</p><p style="margin-left:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The use of other agents that may sedate (e.g, benzodiazepines, opiates, alcohol.)</p><p style="text-align:justify">Delayed epileptiform attacks may occur even in non-epileptic patients, the delay period ranging from a few hours to several days.</p><p><u>Special patient groups</u></p><p><em>Cardiac, circulatory or pulmonary insufficiency and hypovolaemia</em></p><p>As with other intravenous anaesthetic agents, caution should be applied in patients with cardiac,</p><p>respiratory, renal or hepatic impairment or in hypovolaemic or debilitated patients.</p><p style="text-align:justify">Propofol clearance is blood flow dependent, therefore, concomitant medication which reduces cardiac output will also reduce propofol clearance.</p><p style="text-align:justify">Cardiac, circulatory or pulmonary insufficiency and hypovolaemia should be compensated before administration of propofol.</p><p style="text-align:justify">Propofol should not be administered in patients with advanced cardiac failure or other severe myocardial disease except with extreme caution and intensive monitoring.</p><p style="text-align:justify">Due to a higher dosage in patients with severe overweight the risk of haemodynamic effects on the cardiovascular system should be taken into consideration.</p><p style="text-align:justify">Propofol lacks vagolytic activity and has been associated with reports of bradycardia (occasionally profound) and also asystole. The intravenous administration of an anticholinergic agent before induction or during maintenance of anaesthesia should be considered, especially in situations where vagal tone is likely to predominate or when propofol is used in conjunction with other agents likely to cause a bradycardia.</p><p><em>Epilepsy</em></p><p>When propofol is administered to an epileptic patient, there may be a risk of convulsion.</p><p style="text-align:justify">In epileptic patients delayed epileptiform attacks may occur, the delay period ranging from a few hours to several days.</p><p style="text-align:justify">Before anaesthesia of an epileptic patient, it should be checked that the patient has received the antiepileptic treatment. Although several studies have demonstrated efficacy in treating status epilepticus, administration of propofol in epileptic patients may also increase the risk of seizure.</p><p>Use of propofol is not recommended with electroconvulsive therapy.</p><p><em>Patients with disorders of fat metabolism</em></p><p>Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions</p><p>where lipid emulsions must be used cautiously.</p><p><em>Patients with a high intracranial pressure</em></p><p>Special care should be recognised in patients with a high intracranial pressure and a low mean arterial</p><p>pressure as there is a risk of a significant decrease of the intracerebral perfusion pressure.</p><p>&nbsp;</p><p style="text-align:justify"><u>Paediatric population</u></p><p style="text-align:justify">The use of propofol is not recommended in newborn infants as this patient population has not been fully investigated. Pharmacokinetic data (see section 5.2 of the SmPC) indicate that clearance is considerably reduced in neonates and has a very high inter-individual variability. Relative overdose could occur on administering doses recommended for older children and result in severe cardiovascular depression.</p><p style="text-align:justify">Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion is not advised for general anaesthesia in children younger than 1 month of age.</p><p style="text-align:justify">Due to the limited data available, the use of target controlled infusion (TCI) in the paediatric population below 2 years of age cannot be recommended.</p><p style="text-align:justify">Propofol must not be used in patients of 16 years of age or younger for sedation for intensive care as the safety and efficacy of propofol for sedation in this age group have not been demonstrated (see section 4.3).</p><p><u>Advisory statements concerning Intensive Care Unit management</u></p><p style="text-align:justify">Use of propofol emulsion infusions for ICU sedation has been associated with a constellation of metabolic derangements and organ system failures that may result in death. Reports have been received of combinations of the following: Metabolic acidosis, Rhabdomyolysis, Hyperkalaemia, Hepatomegaly, Renal failure, Hyperlipidaemia, Cardiac arrhythmia, Brugada-type ECG (elevated ST-segment and coved T-wave) and rapidly progressive Cardiac failure usually unresponsive to inotropic supportive treatment. Combinations of these events have been referred to as the Propofol infusion syndrome. These events were mostly seen in patients with serious head injuries and children with respiratory tract infections who received dosages in excess of those advised in adults for sedation in the intensive care unit.</p><p style="text-align:justify">The following appear to be the major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents - vasoconstrictors, steroids, inotropes and/or propofol (usually at dose rates greater than 4 mg/kg/h for more than 48 hours).</p><p style="text-align:justify">Prescribers should be alert to these events in patients with the above risk factors and promptly consider decreasing or stopping the propofol dosage when the above signs develop. All sedative and therapeutic agents used in the intensive care unit (ICU), should be titrated to maintain optimal oxygen delivery and haemodynamic parameters. Patients with raised intra-cranial pressure (ICP) should be given appropriate treatment to support the cerebral perfusion pressure during these treatment modifications.</p><p>Treating physicians are reminded if possible not to exceed the dosage of 4 mg /kg/h.</p><p style="text-align:justify"><u>Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously. </u></p><p style="text-align:justify">It is recommended that blood lipid levels should be monitored if propofol is administered to patients thought to be at particular risk of fat overload. Administration of propofol should be adjusted appropriately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the propofol formulation; 1.0 mL of Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion contains approximately 0.1 g of fat.</p><p>&nbsp;</p><p><u>Additional precautions</u></p><p style="text-align:justify">Caution should be taken when treating patients with mitochondrial disease. These patients may be susceptible to exacerbations of their disorder when undergoing anaesthesia, surgery and ICU care. Maintenance of normothermia, provision of carbohydrates and good hydration are recommended for such patients. The early presentations of mitochondrial disease exacerbation and of the &lsquo;propofol infusion syndrome&rsquo; may be similar.</p><p style="text-align:justify">Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion contains no antimicrobial preservatives and supports growth of micro-organisms.</p><p style="text-align:justify">When propofol is to be aspirated, it must be drawn aseptically into a sterile syringe and giving set immediately after opening the ampoule or breaking the vial seal. Administration must commence without delay. Asepsis must be maintained for both propofol and infusion equipment throughout the infusion period. Any infusion fluids added to the propofol line must be administered close to the cannula site. Propofol must not be administered via a microbiological filter.</p><p style="text-align:justify">Propofol and any syringe containing propofol are for single use in an individual patient. In accordance with established guidelines for other lipid emulsions, a single infusion of propofol must not exceed 12 hours. At the end of the procedure or at 12 hours, whichever is the sooner, both the reservoir of propofol and the infusion line must be discarded and replaced as appropriate.</p><p><u>Pain on the injection site</u></p><p style="text-align:justify">To reduce pain on the injection site during induction of anaesthesia with Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion, lidocaine can be injected prior to the propofol emulsion (see section 4.2).</p><p>Intravenous lidocaine must not be used in patients with hereditary acute porphyria.</p><p style="text-align:justify">This medicinal product contains less than 1 mmol (23 mg) sodium per 100 ml, i.e. essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Propofol has been used in association with spinal and epidural anaesthesia and with commonly used premedicants, neuromuscular blocking drugs, inhalational agents and analgesic agents; no pharmacological incompatibility has been encountered. Lower doses of propofol may be required where general anaesthesia or sedation is used as an adjunct to regional anaesthetic techniques.</p><p style="text-align:justify">Profound hypotension has been reported following anaesthetic induction with propofol in patients treated with rifampicin.</p><p style="text-align:justify">Concomitant use of benzodiazepines, parasympatholytic agents or inhalational anaesthetics has been reported to prolong the anaesthesia and to reduce the respiratory rate.</p><p style="text-align:justify">After additional premedication with opioids, the sedative effects of propofol may be intensified and prolonged, and there may be a higher incidence and longer duration of apnoea.</p><p style="text-align:justify">It should be taken into consideration that concomitant use of propofol and medicinal products for premedication, inhalation agents or analgesic agents may potentiate anaesthesia and cardiovascular side effects.</p><p style="text-align:justify">Concomitant use of central nervous system depressants (e.g. alcohol, general anaesthetics, narcotic analgesics) will result in intensification of their sedative effects. When Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion is combined with centrally depressant drugs administered parenterally, severe respiratory and cardiovascular depression may occur.</p><p>&nbsp;</p><p style="text-align:justify">After administration of fentanyl, the blood level of propofol may be temporarily increased with an increase in the rate of apnoea.</p><p>Bradycardia and cardiac arrest may occur after treatment with suxamethonium or neostigmine.</p><p style="text-align:justify">Leucoencephalopathy has been reported with administration of lipid emulsions as used for Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion in patients receiving cyclosporine.</p><p style="text-align:justify">A need for lower propofol doses has been observed in patients taking valproate. When used concomitantly, a dose reduction of propofol may be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p style="text-align:justify">The safety of propofol during pregnancy has not been established. Propofol should not be given to pregnant women except when absolutely necessary. Propofol crosses the placenta and can cause neonatal depression. Propofol can, however, be used during an induced abortion.</p><p style="text-align:justify">High doses (more than 2.5 mg propofol/kg bodyweight for induction or 6 mg propofol/kg bodyweight/h for maintenance of anaesthesia) should be avoided.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3)</p><p><u>Breast-feeding</u></p><p style="text-align:justify">Studies of breast-feeding mothers showed that small quantities of propofol are excreted in human milk. Women should therefore not breastfeed for 24 hours after administration of propofol. Milk produced during this period should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients should be advised that performance at skilled tasks, such as driving and operating machinery, may be impaired for some time after use of propofol.</p><p style="text-align:justify">After administration of Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion, the patient should be kept under observation for an appropriate period of time. The patient should be instructed not to drive, operate machinery, or work in potentially hazardous situations. The patient should not be allowed to go home unaccompanied, and should be instructed to avoid consumption of alcohol.</p><p>Propofol induced impairment is not generally detectable beyond 12 hours (please see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:0cm; text-align:justify">Induction and maintenance of anaesthesia or sedation with propofol is generally smooth with minimal evidence of excitation. The most commonly reported ADRs are pharmacologically predictable side effects of an anaesthetic/sedative agent, such as hypotension. The nature, severity and incidence of adverse events observed in patients receiving propofol may be related to the condition of the recipients and the operative or therapeutic procedures being undertaken.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x005f_x0000_s0" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;margin-left:70.45pt;margin-top:720.25pt;width:440.2pt;
 height:29.75pt;z-index:-251659264;mso-wrap-distance-left:0;
 mso-wrap-distance-right:15.3pt;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><!--[endif]--><!--[if !mso]--><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><!--[endif]--><p>&nbsp;</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;margin-left:70.45pt;margin-top:720.25pt;width:440.2pt;
 height:29.75pt;z-index:-251658240;mso-wrap-distance-left:0;
 mso-wrap-distance-right:15.3pt;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><!--[endif]--><!--[if !mso]--><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><!--[endif]--><p>&nbsp;</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--></p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="2" style="border-color:black; height:10.05pt; vertical-align:top; width:149.15pt"><p style="margin-left:7.2pt; margin-right:0cm; text-indent:-7.2pt"><u>Table of Adverse Drug Reactions </u><strong>System Organ Class</strong></p></td><td style="border-color:black; height:10.05pt; vertical-align:top; width:127.7pt"><p>&nbsp;</p></td><td style="border-color:black; height:10.05pt; vertical-align:top; width:163.35pt"><p>&nbsp;</p></td></tr><tr><td style="height:18.95pt; width:127.7pt"><p style="margin-left:0cm; margin-right:71.8pt; text-align:right"><strong>Frequency</strong></p></td><td style="height:18.95pt; width:163.35pt"><p style="margin-left:0cm; margin-right:65.95pt; text-align:right"><strong>Undesirable Effects</strong></p></td></tr><tr><td style="height:.25pt; vertical-align:top; width:149.15pt"><p>&nbsp;</p></td><td style="height:.25pt; vertical-align:top; width:127.7pt"><p>&nbsp;</p></td><td style="height:.25pt; vertical-align:top; width:163.35pt"><p>&nbsp;</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:44.65pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Immune system disorders:</em></p></td><td style="border-color:black; height:44.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="border-color:black; height:44.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Anaphylaxis &ndash; may include angioedema, bronchospasm, erythema and hypotension</p></td></tr><tr><td style="border-color:black; height:44.4pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.4pt; margin-right:0cm"><em>Metabolism and Nutritional disorder:</em></p></td><td style="height:44.4pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:44.4pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Metabolic acidosis <sup>(5),</sup><br />hyperkalaemia <sup>(5),</sup><br />hyperlipidaemia <sup>(5)</sup></p></td></tr><tr><td style="border-color:black; height:63.1pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Psychiatric disorders:</em></p></td><td style="height:63.1pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:63.1pt; vertical-align:top; width:163.45pt"><p style="margin-left:3.6pt; margin-right:0cm">Euphoric mood, sexual disinhibition.</p><p style="margin-left:3.6pt; margin-right:0cm">Drug abuse and drug dependence</p><p style="margin-left:3.6pt; margin-right:0cm">(8)</p></td></tr><tr><td rowspan="4" style="border-color:black; height:31.7pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Nervous system disorders:</em></p></td><td style="height:31.7pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Common</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/100, &lt;1/10)</p></td><td style="height:31.7pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Headache during recovery phase</p></td></tr><tr><td style="height:88.55pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/10 000, &lt;1/1000)</p></td><td style="height:88.55pt; vertical-align:top; width:163.45pt"><p style="margin-left:7.2pt; margin-right:23.4pt">Epileptiform movements, including convulsions and opisthotonus during induction, maintenance and recovery.</p><p style="margin-left:7.2pt; margin-right:16.2pt">Vertigo, shivering and sensation of cold during recovery</p></td></tr><tr><td style="height:31.7pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="height:31.7pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Postoperative unconsciousness</p></td></tr><tr><td style="height:19.2pt; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:19.2pt; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Involuntary movements</p></td></tr><tr><td rowspan="3" style="border-color:black; height:37.65pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Cardiac disorders:</em></p></td><td style="height:37.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Common</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/100, &lt;1/10)</p></td><td style="height:37.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:3.6pt; margin-right:0cm">Bradycardia <sup>(1)</sup></p><p style="margin-left:3.6pt; margin-right:0cm">and tachycardia during induction</p></td></tr><tr><td style="height:31.95pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="height:31.95pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Pulmonary oedema</p></td></tr><tr><td style="height:31.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:31.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Cardiac arrhythmia <sup>(5)</sup>, cardiac failure (5), (7)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:31.95pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Vascular disorders:</em></p></td><td style="height:31.95pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Common</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/100, &lt;1/10)</p></td><td style="height:31.95pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Hypotension <sup>(2)</sup></p></td></tr><tr><td style="height:31.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Uncommon</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/1000, &lt;1/100)</p></td><td style="height:31.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Thrombosis and phlebitis</p></td></tr><tr><td rowspan="2" style="border-color:black; height:31.95pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.4pt; margin-right:0cm"><em>Respiratory, thoracic and mediastinal disorders:</em></p></td><td style="height:31.95pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Common</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/100, &lt;1/10)</p></td><td style="height:31.95pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Transient apnoea, coughing and singultus during induction</p></td></tr><tr><td style="height:31.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:31.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Respiratory depression (dose dependant)</p></td></tr><tr><td rowspan="2" style="border-color:black; height:31.95pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Gastrointestinal disorders:</em></p></td><td style="height:31.95pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Common</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/100, &lt;1/10)</p></td><td style="height:31.95pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Nausea and vomiting during recovery phase</p></td></tr><tr><td style="height:31.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="height:31.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Pancreatitis</p></td></tr><tr><td style="border-color:black; height:37.95pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.3pt; margin-right:0cm"><em>Hepatobiliary disorders</em></p></td><td style="height:37.95pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:37.95pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Hepatomegaly <sup>(5)</sup></p></td></tr><tr><td style="border-color:black; height:32.15pt; vertical-align:top; width:149.05pt"><p style="margin-left:5.4pt; margin-right:21.6pt"><em>Musculoskeletal and connective tissue disorders:</em></p></td><td style="height:32.15pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:32.15pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Rhabdomyolysis (3), (5)</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td rowspan="2" style="border-color:black; height:31.9pt; vertical-align:top; width:149.05pt"><p style="margin-left:4.35pt; margin-right:0cm"><em>Renal and urinary disorders</em></p></td><td style="border-color:black; height:31.9pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="border-color:black; height:31.9pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Discolouration of urine following prolonged administration</p></td></tr><tr><td style="height:24.75pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:24.75pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Renal failure<sup>(5)</sup></p></td></tr><tr><td rowspan="3" style="border-color:black; height:31.65pt; vertical-align:top; width:149.05pt"><p style="margin-left:3.6pt; margin-right:0cm"><em>General disorders and</em></p><p style="margin-left:3.6pt; margin-right:0cm"><em>administration site conditions:</em></p></td><td style="height:31.65pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very common</p><p style="margin-left:7.2pt; margin-right:0cm">(&gt;1/10)</p></td><td style="height:31.65pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Local pain on induction <sup>(4)</sup></p></td></tr><tr><td style="height:44.4pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="height:44.4pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Tissue necrosis <sup>(10)</sup> following accidental extravascular administration</p></td></tr><tr><td style="height:44.4pt; vertical-align:top; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:44.4pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.4pt; margin-right:0cm">Local pain, swelling, following accidental extravascular administration</p></td></tr><tr><td style="border-color:black; height:19.2pt; width:149.05pt"><p style="margin-left:4.35pt; margin-right:0cm"><em>Investigations</em></p></td><td style="height:19.2pt; width:127.65pt"><p style="margin-left:5.5pt; margin-right:0cm">Frequency not known (9)</p></td><td style="height:19.2pt; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Brugada type ECG (5), (6)</p></td></tr><tr><td style="border-color:black; height:32.4pt; vertical-align:top; width:149.05pt"><p style="margin-left:3.6pt; margin-right:0cm"><em>Injury, poisoning and procedural complications:</em></p></td><td style="height:32.4pt; vertical-align:top; width:127.65pt"><p style="margin-left:7.2pt; margin-right:0cm">Very rare</p><p style="margin-left:7.2pt; margin-right:0cm">(&lt;1/10 000)</p></td><td style="height:32.4pt; vertical-align:top; width:163.45pt"><p style="margin-left:5.3pt; margin-right:0cm">Postoperative fever</p></td></tr></tbody></table><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Serious bradycardias are rare. There have been isolated reports of progression to asystole.</p><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Occasionally, hypotension may require use of intravenous fluids and reduction of the administration rate of propofol.</p><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Very rare reports of rhabdomyolysis have been received where propofol has been given at doses greater than 4 mg/kg/hr for ICU sedation.</p><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->May be minimised by using the larger veins of the forearm and antecubital fossa. With propofol 1 % local pain can also be minimised by the co-administration of lidocaine.</p><p style="margin-left:21.6pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Combinations of these events, reported as &ldquo;Propofol infusion syndrome&rdquo;, may be seen in seriously ill patients who often have multiple risk factors for the development of the events, see section 4.4.</p><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Brugada-type ECG - elevated ST-segment and coved T-wave in ECG.</p><p style="margin-left:21.6pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Rapidly progressive cardiac failure (in some cases with fatal outcome) in adults. The cardiac failure in such cases was usually unresponsive to inotropic supportive treatment.</p><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Abuse of and drug dependence on propofol, predominantly by health care professionals.</p><p style="margin-left:21.6pt; margin-right:0cm; text-indent:-21.6pt"><!--[if !supportLists]-->(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Not known as it cannot be estimated from the available clinical trial data.</p><p style="margin-left:21.6pt; text-indent:-21.6pt"><!--[if !supportLists]-->(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Necrosis has been reported where tissue viability has been impaired.</p><p><u>Reporting of suspected adverse reactions </u></p><p style="margin-right:21.6pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p style="margin-left:10.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Saudi Arabia:</em></strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="border-color:black; height:111.35pt; vertical-align:top; width:362.7pt"><p style="margin-left:7.2pt; margin-right:0cm">-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Toll free phone: 19999</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:10.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Other GCC states:</em></strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Accidental overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression may require lowering of the patient&rsquo;s head and, if severe, use of plasma expanders and pressor agents.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anaesthetics; Other general anaesthetics<br />ATC-Code: N01AX10</p><p><u>Mechanism of action/Pharmacodynamic effects </u></p><p style="text-align:justify">Propofol (2,6-diisopropylphenol) is a short-acting general anaesthetic agent with a rapid onset of action. Depending on the rate of injection, the time to induction of anaesthesia is between 30 and 40 seconds. The duration of action after a single bolus administration is short and lasts, depending on the metabolism and elimination, 4 to 6 minutes.</p><p><u>Clinical efficacy and safety</u></p><p>Under the usual maintenance regimen significant accumulation with either repeated injections or</p><p>infusions of propofol has not been seen. Patients recover consciousness rapidly.</p><p style="text-align:justify">Bradycardia and hypotension reported during induction of anaesthesia may be caused by a cerebral vagotonic effect or inhibition of sympathetic activity. However, haemodynamics generally reverts to normal during maintenance of anaesthesia.</p><p><u>Paediatric population</u></p><p style="text-align:justify">Limited studies on the duration of propofol based anaesthesia in children indicate safety and efficacy is unchanged up to duration of 4 hours. Literature evidence of use in children documents use for prolonged procedures without changes in safety or efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption </u>&nbsp;</p><p>Propofol is bound to plasma proteins for 98 %. Following intravenous administration the</p><p>pharmacokinetics of propofol can be described by a 3-compartment model.</p><p><u>Distribution/ Biotransformation/Elimination</u></p><p style="text-align:justify">Propofol is extensively distributed and rapidly cleared from the body (total body clearance: 1.5 - 2 litres/minute). Clearance occurs by metabolic processes, mainly in the liver <strong>where it is blood flow dependent</strong>, to form inactive conjugates of propofol and its corresponding quinol, which are excreted in urine.</p><p style="text-align:justify">After a single dose of 3 mg/kg intravenously, propofol clearance/kg body weight increased with age as follows: Median clearance was considerably lower in neonates &lt; 1 month old (n=25) (20 ml/kg/min) compared to older children (n=36, age range 4 months &ndash; 7 years). Additionally, inter-individual variability was considerable in neonates (range 3.7 - 78 ml/kg/min). Due to this limited trial data that indicates a large variability, no dose recommendations can be given for this age group.</p><p style="text-align:justify">Median propofol clearance in older aged children after a single 3 mg/kg bolus was 37.5 ml/min/kg (4 - 24 months) (n=8), 38.7 ml/min/kg (11 - 43 months) (n=6), 48 ml/min/kg (1 - 3 years) (n=12), 28.2 ml/min/kg (4 &ndash; 7 years) (n=10) as compared with 23.6 ml/min/kg in adults (n=6).</p><p style="text-align:justify">Due to the limited data available, the use of target controlled infusion (TCI) in the paediatric population below 2 years of age cannot be recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Preclinical data reveal no special hazard for humans based on conventional studies on repeated dose toxicity or genotoxicity. Carcinogenicity studies have not been conducted. Teratogenic effects have not been observed. In local tolerance studies, intramuscular injection resulted in tissue damage around the injection site, paravenous and subcutaneous injection induced histological reactions marked by inflammatory infiltration and focal fibrosis.</p><p style="text-align:justify">Published studies in animals (including primates) at doses resulting in light to moderate anaesthesia demonstrate that the use of anaesthetic agents during the period of rapid brain growth or synaptogenesis results in cell loss in the developing brain that can be associated with prolonged cognitive deficiencies. The clinical significance of these nonclinical findings in not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Soya-bean oil, refined</p><p>Medium-chain triglycerides</p><p>Purified egg phosphatides</p><p>Glycerol</p><p>Oleic acid</p><p>Sodium hydroxide</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life of the medicinal product in its original package before opening: 3 years.
Shelf life after first opening: Product must be used immediately after first opening.
Administration systems with undiluted Propoven 1% MCT/LCT Fresenius emulsion for injection or
infusion should be replaced after 12 hours.
Shelf life after dilution: Medicinal product must be used immediately after dilution. The administration should be completed within 6 hours after dilution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25 &deg;C. Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless glass ampoule(s) (type I) of 20 ml</p><p style="margin-right:104.4pt">Colourless glass vial(s) (type I or II) of 20 ml with a bromobutyl rubber closure Colourless glass vial(s) (type II) of 50 ml with a bromobutyl rubber closure Colourless glass vial(s) (type II) of 100 ml with a bromobutyl rubber closure</p><p>Packs containing 5 glass ampoules with 20 ml emulsion</p><p>&nbsp;</p><p>Packs containing 10 glass ampoules with 20 ml emulsion<br />Pack containing 1 glass vial with 20, 50 or 100 ml emulsion<br />Packs containing 5 glass vials with 20 ml emulsion</p><p>Packs containing 10 glass vials with 20, 50 or 100 ml emulsion<br />Packs containing 15 glass vials with 50 or 100 ml emulsion</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion should not be mixed prior to administration with injection or infusion solutions other than glucose 50 mg/ml (5 %) solution for injection or sodium chloride 9 mg/ml (0.9 %) solution for injection or preservative free lidocaine 10 mg/ml (1 %) solution for injection. The maximum dilution must not exceed 1 part of Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion with 4 parts of glucose 50 mg/ml (5 %) solution for injection or sodium chloride 9 mg/ml (0.9 %) solution for injection (minimum concentration 2 mg propofol/ml). The mixture should be prepared aseptically (controlled and validated conditions preserved) immediately prior to administration and must be administered within 6 hours after preparation (see also section 4.2.).</p><p style="text-align:justify">Final propofol concentration must not be below 2 mg/ml.</p><p style="text-align:justify">Co-administration of a glucose 50 mg/ml (5 %) solution for injection or sodium chloride 9 mg/ml solution for injection or sodium chloride 1.8 mg/ml (0.18 %) solution for injection and glucose 40 mg/ml (4 %) solution for injection with Propoven 1% MCT/LCT Fresenius emulsion for injection or infusion is permitted via a Y-piece connector close to the injection site.</p><p style="text-align:justify">Prior to use, the ampoule neck or rubber membrane should be cleaned using an alcohol spray or a swab dipped in alcohol. After use, tapped containers must be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Deutschland GmbH,
D-61346 Bad Homburg v. d. H., Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>